PROTECT YOUR DNA WITH QUANTUM TECHNOLOGY
Orgo-Life the new way to the future Advertising by AdpathwayIntracameral administration of phenylephrine 1.0% and ketorolac 0.3% during combined cataract surgery and pars plana vitrectomy resulted in aqueous humor ketorolac concentrations that were thirty-three times higher and vitreous humor concentrations that were 809 times higher than those achieved by preoperative topical ketorolac 0.4% eyedrops. The prospective, randomized, controlled clinical study, conducted by lead investigator Eric D. Donnenfeld and colleagues and published in Ophthalmology and Therapy, evaluated eleven adult patients to address a persistent gap in human ocular pharmacokinetic evidence. While topical nonsteroidal anti-inflammatory drops have long served as a standard approach to mitigate intraoperative miosis and postoperative discomfort, their capacity to deliver meaningful therapeutic concentrations into the posterior segment has remained strictly constrained. By measuring drug levels directly from both anterior and posterior chambers using liquid chromatography-tandem mass spectrometry, the investigative team provided the first clinical quantification of vitreous ketorolac following direct intracameral irrigation during surgical intervention.
Surgical trauma during cataract extraction inevitably triggers an intraocular inflammatory cascade within ocular tissues. Mechanical factors during modern phacoemulsification, including corneal incision creation, ultrasound energy dissipation, fluid turbulence, iris touch, and contact with high-velocity nuclear lens fragments, stimulate phospholipase A2. This stimulation releases arachidonic acid, which cyclooxygenase enzymes COX-1 and COX-2 subsequently metabolize into unstable endoperoxide intermediates known as prostaglandin G2 and prostaglandin H2. These intermediates are converted into prostaglandins that induce local vasodilation, increased vascular permeability, intraoperative miosis, ocular pain, hyperemia, photophobia, and reduced postoperative visual acuity. Furthermore, the exacerbation of prostaglandin release is documented during procedures incorporating femtosecond laser technology. To prevent downstream sight-threatening complications, particularly pseudophakic cystoid macular edema, ophthalmic surgeons rely on anti-inflammatory regimens. Nonsteroidal anti-inflammatory medications act directly downstream by inhibiting both COX-1 and COX-2 enzymes, frequently working synergistically alongside upstream corticosteroid agents to suppress prostaglandin biosynthesis and protect fragile retinal structures.
A central clinical dilemma in managing surgical inflammation involves ensuring that therapeutic drug concentrations reach the posterior target tissue, specifically the vitreous cavity, where inflammatory cascades promote cystoid macular edema. While topical ketorolac is a potent inhibitor of both cyclooxygenase isoforms, prior investigations have demonstrated that topical eyedrops yield meager drug penetration into the vitreous body. To establish sufficient biochemical suppression, anti-inflammatory medications must achieve the ninety percent inhibitory concentration, defined for ketorolac as approximately 23 nanograms per milliliter for COX-1 and 150 nanograms per milliliter for COX-2. Earlier clinical evaluations showed that topical administration typically produces vitreous concentrations hovering near or below three nanograms per milliliter, failing to approach the biochemical thresholds required for substantial enzyme inhibition. Consequently, researchers sought to determine whether administering ketorolac intracamerally throughout cataract surgery via continuous irrigation could safely bypass anterior ocular barriers, overcome intraoperative fluid washout, and establish robust, therapeutically relevant concentrations throughout both anterior and posterior segments of the eye.
The clinical trial protocol recruited adult patients aged eighteen years or older scheduled for combined cataract surgery and standard twenty-five-gauge, three-port pars plana vitrectomy at Ophthalmic Consultants of Long Island in New York. The protocol was conducted following the Declaration of Helsinki, received formal approval from the Advarra Institutional Review Board under approval identifier Pro00068701, and was registered at ClinicalTrials.gov under registration identifier NCT06539637. Eligible participants had preoperatively diagnosed structural vitreoretinal pathologies warranting vitrectomy, including epiretinal membrane, macular hole, or symptomatic vitreous floaters, although all ultimately enrolled participants were undergoing surgery specifically for epiretinal membranes. Key exclusion criteria eliminated individuals with previous vitrectomy procedures, intraoperative cataract complications, or posterior capsular tears, ensuring that anatomical integrity was preserved during sampling. Because acquiring intraocular fluid samples entails minor procedural risks like endophthalmitis, retinal detachment, or intraocular hemorrhage, conducting fluid aspiration exclusively in eyes already undergoing planned vitrectomy provided a safe, ethically sound pharmacokinetic testing framework.
Eligible patients were assigned in an equal one-to-one ratio using an electronic randomization generator to receive either topical or intracameral ketorolac. In the control group, patients received topical ketorolac tromethamine 0.4% ophthalmic solution administered four times daily across the three days preceding surgery, concluding with a final dose administered two hours prior to the procedure. In the active study group, patients received an intracameral formulation of phenylephrine 1.0% and ketorolac 0.3%, commercially known as OMIDRIA, which was approved by the United States Food and Drug Administration in 2014 to prevent intraoperative miosis and reduce postoperative pain. Four milliliters of the combination product, supplying 10.16 milligrams per milliliter of phenylephrine and 2.88 milligrams per milliliter of ketorolac, were diluted into a 500-milliliter container of balanced salt solution utilized for continuous anterior chamber irrigation throughout cataract extraction. Demographics of the eleven participants revealed eight Caucasian, two African American, and one Hispanic patient, with axial lengths spanning 23.52 to 25.06 millimeters without extreme myopic or hyperopic refractive errors.
Fluid collection protocols were strictly timed to capture the peak attainable drug concentration associated with each administration method while avoiding dilution artifacts. For control subjects receiving topical drops, anterior chamber aqueous fluid was aspirated immediately at the start of cataract surgery, reflecting the maximal drug accumulation achieved from preoperative dosing before surgical irrigation could wash away topically absorbed medication. For the intracameral group, aqueous fluid was aspirated at the conclusion of cataract surgery immediately prior to initiating vitrectomy, confirming the maximal residual drug concentration left within the anterior chamber following active irrigation. Anterior chamber sampling employed a half-inch twenty-seven-gauge cannula to draw 0.5 to 1.0 milliliter of aqueous humor. Subsequently, undiluted mid-vitreous cavity samples measuring 0.5 to 1.0 milliliter were extracted in all eyes at the initiation of the twenty-five-gauge vitrectomy before activating posterior infusion lines. Collected ocular specimens were immediately frozen, maintained on dry ice, and transported overnight to Emery Pharma for masked laboratory evaluation.
Because authentic human ocular humors are exceptionally scarce, bioanalytical quantification was achieved utilizing an innovative, highly sensitive assay developed and validated under international ICH M10 bioanalytical method guidelines. The testing laboratory utilized human plasma as a surrogate analytical matrix, quantifying drug concentrations through liquid chromatography-tandem mass spectrometry to overcome the physical constraints of minute specimen volumes. To maintain rigorous analytical neutrality, both the testing laboratory personnel and the biostatistician conducting subsequent statistical analyses were fully masked to treatment allocation. Continuous quantitative variables were analyzed using descriptive parameters including means, standard deviations, medians, and interquartile ranges, with comparative significance established using independent-samples t-tests or non-parametric Mann-Whitney U tests at a two-sided significance threshold of alpha less than 0.05. Although the modest enrollment reflected practical and ethical limitations inherent to intraocular sampling rather than statistical power calculations, the standardized analytical methodology provided precise measurement of ketorolac levels down to a lower limit of quantification of 2.5 nanograms per milliliter.
Analytical results revealed substantial quantitative disparities between the two delivery methods in both ocular chambers. In the aqueous humor, eyes receiving intracameral ketorolac demonstrated a mean concentration of 20,868.2 plus or minus 7342.4 nanograms per milliliter, with a median of 24,422.6 nanograms per milliliter and an interquartile range of 19,798.2 to 24,755.7 nanograms per milliliter. Conversely, eyes treated with topical eyedrops displayed a mean aqueous concentration of 635.1 plus or minus 909.6 nanograms per milliliter, with a median of 176.2 nanograms per milliliter and an interquartile range of 112.3 to 821.0 nanograms per milliliter, demonstrating a statistically significant thirty-three-fold advantage for intracameral delivery with a p-value of less than 0.0001. In the vitreous humor, the divergence proved even more pronounced: intracameral irrigation yielded a mean vitreous concentration of 2508.8 plus or minus 4477.6 nanograms per milliliter, compared to 3.1 plus or minus 7.7 nanograms per milliliter in the topical cohort, yielding a statistically significant difference with a p-value of 0.0004.
The pharmacokinetic findings offer important context when evaluated against previously published ocular drug penetration literature. The mean aqueous concentration of 635 nanograms per milliliter observed in the topical control arm aligns closely with historical data from Bucci and associates, who reported 688 nanograms per milliliter following topical administration, while surpassing values from Katsev and colleagues, whose preoperative levels ranged from 4.9 to 369 nanograms per milliliter. Katsev’s team observed that intraoperative irrigation and viscoelastic materials washed out topically delivered ketorolac, leaving undetectable concentrations in two-thirds of patients by surgery’s end. In the vitreous, topical levels of 3.1 nanograms per milliliter mirrored findings by Heier and colleagues, who documented 2.8 nanograms per milliliter, while falling below Schoenberger’s reported 7.55 nanograms per milliliter. Crucially, five of the six topical patients in the present trial exhibited vitreous levels below the lower limit of quantification of 2.5 nanograms per milliliter. In contrast, intracameral administration maintained levels dramatically exceeding the ninety percent inhibitory concentrations of 23 nanograms per milliliter for COX-1 and 150 nanograms per milliliter for COX-2.
The authors postulated that high vitreous ketorolac concentrations resulted from positive infusion pressure during phacoemulsification, which promotes balanced salt solution transit across the zonules into the posterior segment, a mechanism corroborated by clinical observations of retrozonular fluid flow and retained nuclear lens fragments. While cystoid macular edema characteristically manifests four to six weeks postoperatively, intraoperative prostaglandin inhibition at the time of surgical trauma represents a critical prophylactic step. Nevertheless, the authors emphasized that this small investigation must be interpreted strictly as an exploratory pharmacokinetic study rather than a definitive comparative efficacy trial. Limitations include the small cohort of eleven eyes, lack of longitudinal postoperative concentration tracking, unmeasured irrigation volumes, and unaccounted physiological differences in ocular blood flow, eye size, and vitreous volume. Future prospective clinical investigations with larger cohorts remain necessary to corroborate these initial observations and establish whether superior intraoperative vitreous drug levels translate directly into enhanced protection against postoperative macular edema.
Subject of Research: Ocular pharmacokinetics of intracameral versus topical ketorolac in combined eye surgery
Article Title: Aqueous and Vitreous Ketorolac Levels in Combined Cataract and Pars Plana Vitrectomy with Intracameral Ketorolac 0.3% Versus Topical Ketorolac 0.4%
Article References: Donnenfeld, E. D., Narain, S., Shoshany, T., Perry, H. D., & Connell, S. B. (2026). Aqueous and Vitreous Ketorolac Levels in Combined Cataract and Pars Plana Vitrectomy with Intracameral Ketorolac 0.3% Versus Topical Ketorolac 0.4%. Ophthalmology and Therapy. https://doi.org/10.1007/s40123-026-01525-8
Image Credits: AI Generated
DOI: 10.1007/s40123-026-01525-8
Keywords: ketorolac, phenylephrine, OMIDRIA, cataract surgery, pars plana vitrectomy, aqueous humor, vitreous humor, intracameral administration, topical ophthalmic drops, ocular pharmacokinetics, cystoid macular edema, cyclooxygenase inhibition, prostaglandin synthesis, liquid chromatography-tandem mass spectrometry, phacoemulsification, epiretinal membrane, anti-inflammatory drug delivery


2 days ago
3




















English (US) ·
French (CA) ·